发布求助
文献互助 智能选刊 最新文献

Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases最新文献

筛选
英文 中文
Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis - Peginterferon Beta-1a, Daclizumab Beta, Natalizumab 使用定量药理学开发多发性硬化症治疗蛋白的案例-聚乙二醇干扰素β -1a, Daclizumab β， Natalizumab
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH18
Xiao Hu, Yaming Hang, Lei Diao, K. Muralidharan, I. Nestorov
{"title":"Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis - Peginterferon Beta-1a, Daclizumab Beta, Natalizumab","authors":"Xiao Hu, Yaming Hang, Lei Diao, K. Muralidharan, I. Nestorov","doi":"10.1002/9781119289234.CH18","DOIUrl":"https://doi.org/10.1002/9781119289234.CH18","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114563909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Translational Considerations in Developing Bispecific Antibodies: What Can We Learn from Quantitative Pharmacology? 开发双特异性抗体的翻译考虑:我们能从定量药理学中学到什么?
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH9
Pradeep B. Lukka, Santosh Wagh, B. Meibohm
{"title":"Translational Considerations in Developing Bispecific Antibodies: What Can We Learn from Quantitative Pharmacology?","authors":"Pradeep B. Lukka, Santosh Wagh, B. Meibohm","doi":"10.1002/9781119289234.CH9","DOIUrl":"https://doi.org/10.1002/9781119289234.CH9","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124702205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases 药物计量学和系统药理学在当前和新兴的炎症性肠病生物制剂中的应用
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH10
S. Ait-Oudhia, Y. Lien, S. Basu, L. Lesko, S. Schmidt
{"title":"Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases","authors":"S. Ait-Oudhia, Y. Lien, S. Basu, L. Lesko, S. Schmidt","doi":"10.1002/9781119289234.CH10","DOIUrl":"https://doi.org/10.1002/9781119289234.CH10","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132743797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects - Some Considerations 定量药理学方法选择最佳剂量和研究决定儿童治疗性单克隆抗体处置的重要因素-一些考虑
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH13
D. Hardiansyah, C. Ng
{"title":"Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects - Some Considerations","authors":"D. Hardiansyah, C. Ng","doi":"10.1002/9781119289234.CH13","DOIUrl":"https://doi.org/10.1002/9781119289234.CH13","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"71 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131879374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Vedolizumab-A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease 维多利单抗——定量药理学应用于炎症性肠病治疗生物制剂开发的案例
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH16
M. Rosario, N. Dirks, D. Mould, Scholz Catherine, T. Wyant, A. Parikh, I. Fox
{"title":"Vedolizumab-A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease","authors":"M. Rosario, N. Dirks, D. Mould, Scholz Catherine, T. Wyant, A. Parikh, I. Fox","doi":"10.1002/9781119289234.CH16","DOIUrl":"https://doi.org/10.1002/9781119289234.CH16","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"9 47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121572410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Systemic Lupus Erythematosus - Belimumab 使用定量药理学开发系统性红斑狼疮治疗蛋白的案例-贝利姆单抗
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH17
H. Struemper
{"title":"Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Systemic Lupus Erythematosus - Belimumab","authors":"H. Struemper","doi":"10.1002/9781119289234.CH17","DOIUrl":"https://doi.org/10.1002/9781119289234.CH17","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130139588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pharmacokinetics-Based Dosing for Therapeutic Monoclonal Antibodies in Inflammatory Bowel Disease 基于药代动力学的炎症性肠病治疗性单克隆抗体剂量
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH11
N. V. Casteele, W. Sandborn
{"title":"Pharmacokinetics-Based Dosing for Therapeutic Monoclonal Antibodies in Inflammatory Bowel Disease","authors":"N. V. Casteele, W. Sandborn","doi":"10.1002/9781119289234.CH11","DOIUrl":"https://doi.org/10.1002/9781119289234.CH11","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127135205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins for Plaque Psoriasis - Guselkumab 使用定量药理学开发斑块型银屑病治疗蛋白的案例- Guselkumab
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH15
Z. Yao, Yaowei Zhu, Chuanpu Hu, Yang Chen, Shu Li, B. Randazzo, Zhenhua Xu, Amarnath Sharma, Honghui Zhou
{"title":"Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins for Plaque Psoriasis - Guselkumab","authors":"Z. Yao, Yaowei Zhu, Chuanpu Hu, Yang Chen, Shu Li, B. Randazzo, Zhenhua Xu, Amarnath Sharma, Honghui Zhou","doi":"10.1002/9781119289234.CH15","DOIUrl":"https://doi.org/10.1002/9781119289234.CH15","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"318 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123776504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tutorial: Numerical (NONMEM) Implementation of the Target-Mediated Drug Disposition Model 教程:目标介导药物处置模型的数值(NONMEM)实现
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH8
L. Gibiansky, E. Gibiansky
{"title":"Tutorial: Numerical (NONMEM) Implementation of the Target-Mediated Drug Disposition Model","authors":"L. Gibiansky, E. Gibiansky","doi":"10.1002/9781119289234.CH8","DOIUrl":"https://doi.org/10.1002/9781119289234.CH8","url":null,"abstract":"","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116637551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Disease Interception in Autoimmune Diseases: From a Conceptual Framework to Practical Implementation 自身免疫性疾病的疾病拦截:从概念框架到实际实施
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases Pub Date : 2019-02-15 DOI: 10.1002/9781119289234.CH1
A. Suri
{"title":"Disease Interception in Autoimmune Diseases: From a Conceptual Framework to Practical Implementation","authors":"A. Suri","doi":"10.1002/9781119289234.CH1","DOIUrl":"https://doi.org/10.1002/9781119289234.CH1","url":null,"abstract":"The hallmark of autoimmunity, and perhaps many immune-mediated inflammatory diseases, is the inappropriate recognition of self-tissue resulting in subsequent effector reactions that ultimately damage the host. Numerous components may underlie these outcomes and likely include lack of central immune tolerance to self, breakdown of peripheral tolerance mechanisms that control inflammation, relevant stress signals that enhance and/or modify antigenicity of self-tissues, and a complex interplay between the host and the environment; including the emergent immuno-regulatory role of the microbiome. Much of the historical therapeutic success has focused on approaches that broadly dampen or modulate inflammatory mediators (e.g. success of anti-cytokine antibodies directed against tumor necrosis factor (TNF), or interleukins such as IL-6, IL-17, IL-1 in rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis or small molecule kinase inhibitors) with little to no understanding of the earliest molecular triggers that underpin disease initiation [1, 2]. While anti-inflammatory approaches have yielded symptomatic benefits for the patients, a significant unmet medical need still exists particularly from the viewpoint of sustained disease remission and cessation of tissue-destructive biological processes. To this end, the ultimate therapeutic goal for autoimmune diseases would be to restore immune homeostasis as evidenced by inhibition of self-reactivity leading to reestablishment of a self-tolerant state.","PeriodicalId":162868,"journal":{"name":"Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases","volume":"431 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115933674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信